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Atherosclerosis and arterial restenosis are disease
processes involving the accumulation of vascular
smooth muscle cells following vascular injury. Key
events leading to these processes are migration and pro-
liferation of these cells. Here, we demonstrate that
GAS6, encoded by the growth arrest-specific gene 6, in-
duces a directed migration (chemotaxis) of both rat and
human primary vascular smooth muscle cells while
showing only marginal mitogenic potential in human
vascular smooth muscle cells. GAS6 stimulation induces
Axl autophosphorylation in human vascular smooth
muscle cells, indicating that specific GAS6-Axl interac-
tions may be associated with GAS6-directed chemotaxis.
To test this hypothesis, vascular smooth muscle cells
overexpressing Axl were generated by gene transfer and
assessed for their ability to migrate along a GAS6 gradi-
ent. These Axl overexpressors exhibited 2–5-fold in-
creased sensitivity to GAS6-induced chemotaxis. Fur-
thermore, vascular smooth muscle cells expressing the
kinase dead mutant of Axl or exposure to the soluble Axl
extracellular domain showed attenuated GAS6-induced
migration. Taken together, these results suggest that
GAS6 is a novel chemoattractant that induces Axl-medi-
ated migration of vascular smooth muscle cells. The sep-
aration of mitogenesis from migration provided by this
study may enhance the molecular dissection of cell mi-
gration in vascular damage.
Atherosclerosis and arterial restenosis is a consequence of
accumulation of connective tissue in conjunction with prolifer-
ation and directed migration of vascular smooth muscle cells
(VSMC)1 (1). To evaluate potential in vivo effects of prolifera-
tion and directed migration of VSMC following treatment of
agonists or growth factors, primary, cultured VSMC have
proven to be an excellent in vitro model system.
In cultured rat VSMC, GAS6, encoded by the growth arrest-
specific gene 6 (gas6), was identified and characterized as an
important growth-potentiating factor whose expression is up-
regulated after serum starvation (2–4). GAS6 possesses a 44%
sequence identity with protein S, an anti-coagulation factor (4).
In quiescent VSMC, GAS6 stimulation specifically potentiates
proliferation induced by Ca21-mobilizing receptors indicating
that GAS6 may be involved in regulating signaling pathways
mediated by heterotrimeric guanine nucleotide-binding (G)
protein-coupled receptors. GAS6 alone, however, is able to pre-
vent growth arrest-induced apoptosis in these cells (5). We
have identified GAS6 to be the ligand for Axl, a member of a
tyrosine kinase receptor family whose extracellular domains
resemble cell adhesion molecules (6–13). It was subsequently
demonstrated that GAS6 is also a ligand for Sky, an Axl-
related receptor tyrosine kinase (14–16). In addition, it was
recently shown that GAS6 may be the ligand for another Axl
family member, Mer, although the affinity of the GAS6-Mer
interaction is much lower than that for Axl and Sky (17). In rat
VSMC, a high affinity, specific binding site for GAS6 was
characterized and the molecular weight of the cross-linked
complex coincided with that of the AxlzGAS6 complex (18). In
support of the hypothesis that the GAS6/Axl pathway is in-
volved in G protein receptor-mediated signaling events is re-
cent evidence indicating that Axl expression is up-regulated by
G protein-coupled receptor agonists both in cultured VSMC
and in vivo following balloon injury.2 Thus, these results sug-
gest that GAS6 may be important in VSMC biology and may
involve signaling by its receptor, Axl, in conjunction with G
protein receptor-mediated signaling pathways.
In addition to its biological implications in cultured VSMC,
the function of GAS6 has been investigated in several other cell
systems. In 3T3 cells, it was shown that GAS6 mediates both
mitogenic and survival activities through ARK, the murine
homologue of Axl (20, 21). This mitogenic effect is also observed
in cultured human Schwann cells where GAS6 is found to
stimulate DNA synthesis in these cells (22). By contrast, in
murine hematopoietic 32D cells, we have demonstrated that
exogenous GAS6 stimulation results in Axl autophosphoryla-
tion but no mitogenic or anti-apoptotic responses (23). In these
cells, GAS6 promotes Axl-mediated adhesion, suggesting adhe-
sion as one function for the GAS6-Axl interaction (24). Thus,
the GAS6-associated biology appears complex and may be de-
pendent upon the cellular context in which Axl and GAS6
operate.
In light of the findings that GAS6 appears important in the
growth regulation of VSMC, we sought to investigate the effect
of Axl-GAS6 interactions on other biological consequences in
these cells. Here, we describe that in both rat and human
primary VSMC, GAS6 can act as a chemoattractant for migra-
tion in modified Boyden chambers (25, 26). The chemotactic
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nature of the GAS6-induced migration is evidenced in that a
GAS6 gradient is necessary for this action. The specificity of
GAS6-induced migration was further confirmed in that addi-
tion of purified Axl extracellular domain (ECD) attenuates
migration. In agreement with previous studies in rat VSMC,
GAS6 alone does not induce proliferation of human AoSMC
(aortic smooth muscle cells). However, in response to GAS6,
human AoSMC overexpressing Axl augment cell migration
whereas ectopic expression of the Axl kinase dead mutant
reduces the ligand-associated migration. Thus, these results
strongly suggest that GAS6-Axl interactions induce chemotaxis
of VSMC.
EXPERIMENTAL PROCEDURES
VSMC Cultures—Primary rat aortic VSMC were prepared and es-
tablished essentially as described by Haller et al. (27). Briefly, thoracic
aortas from young Sprague-Dawley rats were stripped of fatty and
connective tissues and endothelium. The aortas were minced under
aseptic conditions and treated with a combination of collagenase, elas-
tase, and trypsin inhibitors as described (27). Primary rat aortic SMC
were maintained in Dulbecco’s modified Eagle’s medium (DMEM-H)
supplemented with 10% fetal bovine serum and penicillin/streptomycin
(Life Technologies, Inc.). The phenotype of the primary VSMC was
confirmed by staining the cells with smooth muscle-specific a-actin
antibodies (Sigma) (27). Primary AoSMC were purchased from Clonetics,
Inc. and maintained according to the provided instructions. Both rat
and human cells for the experiments described in this study were used
at passages 2–8.
Migration Assays—Migration assays were performed with modified
Boyden chambers as described (26). Twenty-four well polyvinylidene
difluoride filter inserts (8-mm pore diameter, Beckon Dickinson) were
coated with a phosphate-buffered saline solution containing 100 mg/ml
type I collagen (UBI) (26). To assemble modified Boyden chambers, the
coated inserts were dropped into individual wells containing various
factors in 0.8 ml of DMEM-H. Primary VSMC were gently trypsinized,
counted, and allowed to recover in DMEM-H complete media for 1 h at
room temperature with gentle rocking. Cells were then gently spun
down and resuspended in DMEM-H containing 0.1% BSA at 1 3 105
cells/ml. Aliquots of 0.5 ml of cells were then transferred into the upper
well of each assembled chamber. The chambers were incubated for 16 h
at 37 °C in an atmosphere of 5% CO2. Migration assays were also
performed using 48-well micro-chemotaxis chambers (NeuroProbe, Inc.,
Cabin John, MD) as described (25). Similar results were obtained fol-
lowing shortened incubation periods (4 h) confirming the reproducibil-
ity of the assay.
Measurement of DNA Synthesis—Human AoSMC were seeded in
24-well plates and cultured in media recommended by the manufac-
turer (Clonetics, Inc.). At confluence, cells were rendered quiescent by
serum starvation for 48–72 h. Following replacement of the culture
medium with fresh medium, cells were stimulated with GAS6, PDGF,
or BSA for re-entry of cell cycle. At various time points following ligand
stimulation, cells were pulsed with 1.5 mCi/well [3H]thymidine for 4 h.
[3H]Thymidine incorporation was measured after trichloroacetic acid
precipitation as described (2).
Generation of Axl-overexpressing AoSMC Cell Lines—For retrovival
infection of primary human AoSMC, amphotropic viruses were har-
vested from conditioned media of PA317 packaging cells following
transfection of various Axl constructs (24).3 Of three Axl constructs
generated in the retroviral-based vector, pLXSN, the wild-type and the
kinase dead (substitution of Arg for Lys at amino acid position 567) Axl
constructions have been described (24).3 The 1B1 construct contains a
wild-type Axl cDNA sequence from which further Axl overexpression is
induced by Moloney murine leukemia virus promoter mutations (data
not shown). G418-resistant clones were selected and pooled to estab-
lished cell lines. Passaging of these cells was kept to a minimum prior
to protein analysis and migration assays to ensure the integrity of
primary cell properties.
Immunoprecipitation and Western Blot Analysis—For Axl autophos-
phorylation assays, human AoSMC were grown to confluence in
150-mm plates and subjected to serum starvation for 48–72 h in
DMEM-H. GAS6 stimulation was performed as described (23). Follow-
ing 10 min stimulation at 37 °C, cells were washed with ice-cold phos-
phate-buffered saline and lysed in ice-cold HNTG lysis buffer (50 mM
HEPES, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl2, 10% glycerol, 1
mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 1 mM Na3VO4,
0.15 TIU/ml aprotonin). Preparation of cell lysates for immunoprecipi-
tation with anti-Axl polyclonal antibodies (1:250) as well as Western
blot analysis were performed as described (23). Following electro-
phoretic transfer onto polyvinylidine difluoride membrane (Millipore),
the phosphorylation status of the Axl receptor was examined by incu-
bating the membrane with anti-phosphotyrosine antibodies (PT-66,
1:1000) (Sigma) followed by horseradish peroxidase-conjugated, donkey
anti-mouse secondary antibodies (1:5000) (Amersham) (23). Western
blots were developed with ECL reagents (Amersham). For analysis of
ectopic Axl expression, AoSMC were lysed as described above. Equal
amounts of total proteins (50–100 mg) from each cell line were then
analyzed for Axl expression by Western blotting using anti-Axl poly-
clonal antibodies (1:1000) (23).
Production and Purification of Axl-ECD from Sf9 Insect Cells—The
extracellular domain of the Axl receptor (Axl-ECD) was expressed in
Sf9 insect cells using the baculovirus expression system (6, 24). Pro-
duction and purification of the Axl-ECD protein was carried out as
described (6, 24).
RESULTS AND DISCUSSION
Directed migration of VSMC from tunica media to intima
and subsequent proliferation of neointima are two key events
involved in atherogenesis following both the mechanical injury
and inflammatory responses of the arteries (28, 29). Given the
findings that GAS6 may play a role as a cofactor in prolifera-
tion for rat VSMC, we wished to investigate whether GAS6 also
possessed chemotactic properties in these cells. To examine
whether GAS6 could induce chemotaxis of VSMC, migration
assays in modified Boyden chambers were conducted (Refs. 25
and 26, also see “Experimental Procedures”). As shown in Fig.
1A, human recombinant GAS6 induced chemotaxis of rat
VSMC at approximately 6-fold greater than controls. A dose-
response experiment showed that 200 ng/ml GAS6 induced the
maximal level of migration, a concentration of GAS6 compara-
ble to that observed for inducing maximal Axl autophosphoryl-
ation (data not shown) (6). In comparison, PDGF-BB, the most
3 A. Burchert, E. C. Attar, P. McCloskey, Y.-W. C. Fridell, and E. T.
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FIG. 1. GAS6 induces directed migration of rat (A) and human
(B) VSMC. Migration assays were performed as described under “Ex-
perimental Procedures.” Modified Boyden chambers were assembled by
adding DMEM-H containing BSA (200 ng/ml), ECD: purified Axl-ECD
(200 ng/ml), human recombinant GAS6 (200 ng/ml), a combination of
Axl-ECD and GAS6, epidermal growth factor (EGF) (100 ng/ml) (UBI),
or PDGF-BB (30 ng/ml) (Genzyme) in a total volume of 0.8 ml to the
lower well of the chambers. Filters were coated with collagen I (100
mg/ml) and then placed in the apparatus. Fifty thousand cells resus-
pended in 0.5 ml of DMEM-H were then added to the upper well of the
chamber. For experiments assaying the requirement for a GAS6 gradi-
ent, cells containing 200 ng/ml GAS6 in DMEM-H were placed in the
upper well of the chamber (GAS6/U&L). Following 16 h of incubation
at 37 °C, cells were fixed, stained, and counted at 3 100–200 magnifi-
cation. Each bar represents the average (6S.D.) fold increase in migra-
tion (subtracted from BSA control) as determined from three to five
independent experiments. Migration assays were also performed using
48-well micro-chemotaxis chambers as described (NeuroProbe, Inc.)
(25). Reproducible results were obtained following shortened incubation
periods (4 h) (see “Experimental Procedures”).
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potent chemoattractant for VSMC described to date, induced
chemotaxis of these cells 4–5-fold greater than that induced by
GAS6 (Fig. 1A) (19, 28). The chemotactic but not chemokinetic
effect of GAS6 on these cells was evidenced by the fact that a
GAS6 gradient induced directed migration. When the same
concentration of GAS6 was included in both upper and lower
wells of the chambers, migration of these cells was reduced to
one-third to one-half of that seen when gradients were main-
tained (Fig. 1A). Furthermore, this effect can be attenuated by
the addition of soluble, recombinant Axl extracellular domain
protein (Axl-ECD) at a 1:1 molar ratio in the lower well of the
chambers indicating that GAS6 serves as the signal for chemo-
taxis of these cells (6, 24).
To verify that the chemotactic effect induced by human
GAS6 in rat VSMC is physiologically relevant, we investigated
whether human recombinant GAS6 would induce directed mi-
gration of primary human AoSMC in a similar fashion. As
expected, human AoSMC migrated in response to GAS6 in the
same manner as observed in rat VSMC (Fig. 1B). Chemotaxis
of these cells toward GAS6 was dependent upon the presence of
a GAS6 concentration gradient between the upper and lower
wells of the modified Boyen chamber (Fig. 1B). Again, GAS6-
induced chemotaxis was reduced by the presence of purified
Axl-ECD. Finally, epidermal growth factor, a known mitogen
for VSMC that has no chemoattractant properties showed no
effect in inducing migration of these cells demonstrating that
mitogenicity and cell migration can be separated by these in
vitro assays (Fig. 1B). Thus, GAS6 functions as a chemoattrac-
tant for VSMC migration in vitro.
To determine if GAS6 alone can act as a mitogen in human
AoSMC, DNA synthesis was measured in these cells following
GAS6 stimulation. As shown in Fig. 2, marginal mitogenic
effects were detected in quiescent cells when stimulated with
GAS6 (1.5-fold increase as compared with control) whereas
PDGF-BB treatment induced potent mitogenesis of these cells
(Fig. 2). Although previous studies indicated that GAS6 poten-
tiates a 2-fold increase in proliferation of rat VSMC in the
presence of thrombin, we did not observe such an increase in
cultured human AoSMC using human GAS6 under the same
conditions (data not shown) (2). Therefore, we hypothesize that
the primary function of human GAS6 in vivo is to induce
migration of AoSMC without stimulating proliferation of these
cells.
We sought to identify specific ligand-receptor interactions
responsible for GAS6-induced VSMC migration. Following
GAS6 stimulation, Axl-specific antibodies were used to immu-
noprecipitate lysates from quiescent AoSMC. As shown in Fig.
3, when probed with anti-phosphotyrosine antibodies, GAS6
stimulation resulted in Axl autophosphorylation. Thus, GAS6-
Axl interactions may be associated with GAS6-induced migra-
tion of human AoSMC. Several attempts were made to deter-
mine the phosphorylation status of Mer and Sky following
GAS6 stimulation in AoSMC. However, due to the lack of
suitable Mer and Sky antibodies for these analyses, the exact
involvement of these two receptor kinases in this process re-
mains to be determined. To further test the hypothesis that Axl
mediates GAS6-induced AoSMC migration, primary human
AoSMC ectopically expressing Axl were generated.3 Migration
assays were then performed to assess the ability of these Axl-
expressing cells to migrate in the presence of GAS6 in the lower
well of the modified Boyden chamber (25, 26). Two AoSM cell
lines overexpressing the wild-type Axl were generated. As dem-
onstrated in Fig. 4A, Axl/AoSMC expressed moderately higher
Axl than the parental cells whereas a dramatic overexpression
of Axl was achieved in 1B1/AoSMC.3 When tested for migra-
tion, moderate Axl-overexpressors (Axl/AoSMC) exhibited a
2.5–3-fold increase in GAS6-dependent migration as compared
with parental AoSMC (Fig. 4B). By contrast, 1B1/AoSMC dem-
onstrated a further increase (up to 5-fold) in numbers of mi-
grated cells as compared with parental AoSMC in response to
GAS6 (Fig. 4B). In addition, the increased migration seen in
Axl-overexpressing AoSMC was again attenuated by the appli-
cation of the Axl-ECD in the lower well of the chambers (data
not shown). To further confirm the direct involvement of Axl in
this process, AoSMC expressing the kinase dead mutant of Axl
(AxlK567R) were generated (Fig. 4A) (24). Significantly, when
tested for chemotaxis, these cells exhibited reduced migration
in response to GAS6 as compared with the uninfected parental
AoSMC (Fig. 4B). In the same assays, the parental AoSMC and
the ectopic Axl-expressing AoSM cells had identical migratory
responses to PDGF-BB, indicating the specificity of Axl-de-
FIG. 2. GAS6 does not induce mitogenesis in human AoSMC. In
24-well plates, confluent human VSMC were rendered quiescent after
incubation in DMEM-H for 48 h. For ligand stimulation, fresh
DMEM-H containing BSA (200 ng/ml), GAS6 (200 ng/ml), or PDGF (50
ng/ml) was added to each well. At the indicated times, cells were pulsed
with 1.5 mCi/well [3H]thymidine for 4 h.
FIG. 3. Axl phosphorylation in response to exogenous GAS6
stimulation in human AoSMC. Primary human AoSMC were mock
stimulated (2), stimulated with 1 3 GAS6 (200 ng/ml) or 2 3 GAS6 (400
ng/ml) for 10 min at 37 °C. Cells were lysed and subjected to immuno-
precipitation with an anti-Axl polyclonal antibody at 1:250. Subsequent
Western blotting analysis with an anti-Tyr(P) antibody at 1:1000 (PT-
66, Sigma) was performed as described under “Experimental Proce-
dures.” Molecular weight markers are indicated. The position of the
p140 Axl is indicated.
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pendent effects on migration in these cell lines (data not
shown). Taken together, these results strongly indicate that
the Axl receptor mediates GAS6-induced migration of AoSMC
in vitro and that the kinase activity of the Axl receptor is
involved in migration in response to GAS6. Furthermore, the
fact that AxlK567R bearing AoSM cells showed reduced levels
of GAS6-induced migration suggests that other Axl-related
tyrosine kinase receptors may not be playing a significant role
in this process.
Melaragno and co-workers recently showed an up-regulation
of Axl expression 7–14 days following balloon injury of rat
carotid arteries.2 This increased Axl expression correlates well
with the time course of neointima thickening due to medial
VSMC migration post-injury (29). Furthermore, the immuno-
histochemical staining of injured vessels showed increased Axl
expression localized to the neointima.2 Northern blot analysis
on denuded vessels following balloon injury of rat carotid ar-
teries has revealed an increase of GAS6 transcripts in these
tissues.4 In light of these findings, we suggest the following
hypothesis for Axl and GAS6 involvement in response to arte-
rial injury: following arterial injury, increased local GAS6 con-
centration permits formation of GAS6 gradient. This gradient
may then induce the migration of medial smooth muscle cells to
the intima. The subsequent up-regulation of Axl expression
post-injury, perhaps influenced by G protein-coupled agonists
on site, thus renders VSMC more sensitive to GAS6 for prolif-
eration. These processes may, in turn, contribute to atheroscle-
rotic plaque formation and arterial restenosis.
In summary, we have uncovered a novel function for human
recombinant GAS6 as a chemoattractant in cultured rat and
human VSMC. Significantly, we have demonstrated that
GAS6-induced migration appears to be mediated by its recep-
tor, Axl. Further insights into atherogenesis can be gained by
determining the signaling pathways activated by GAS6-Axl
interactions in these cells. Thus, interventions may be devised
to block specific downstream effectors following Axl activation
to alleviate the consequences of vascular damage.
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FIG. 4. Ectopic expression of wild-type and the kinase dead
mutant of Axl in human AoSMC (A) and migration assays (B) of
these cells. A, 100 mg of total protein from each cell line was separated
on a 7.5% SDS-polyacrylamide gel. Western blot analysis with anti-Axl
antibody (1:1000) was performed. AxlK567R is the kinase dead Axl
mutant. Axl contains the wild-type Axl cDNA sequence. 1B1 construct
containing a wild-type Axl cDNA sequence overexpresses the Axl pro-
tein. B, for migration assays, modified Boyden chambers were assem-
bled by adding either BSA (200 ng/ml) or human recombinant GAS6
(200 ng/ml) in DMEM-H to the lower well of the chambers. Filters were
coated with collagen I and then placed in the apparatus. Fifty thousand
cells resuspended in DMEM-H were then added to the upper well of the
chamber. Following 16 h of incubation at 37 °C, cells were fixed,
stained, and counted at 3 100–200 magnification. Each bar represents
the average (6S.D.) fold increase in migration (subtracted from migra-
tion of parental AoSMC) as determined from three independent
experiments.
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